LUND, Sweden, March 12, 2021 /PRNewswire/ -- Immunovia has
today published the annual report for 2020. It is available
on Immunovia's website.
"After many years of intensive preparation, Immunovia is close
to a commercial breakthrough with the launch of our blood test for
early detection of pancreatic cancer - IMMray™ PanCan-d - in the
first quarter of 2021. Thus, Immunovia will be the first company in
the world to launch a test that, by virtue of its early detection
capabilities, can provide improved care and survival of pancreatic
cancer patients," said Patrik
Dahlen, CEO Immunovia.
The annual report can be downloaded in pdf format and is
available on Immunovia's website:
immunovia.com/en/investors/financial-reports/
For more information, please contact:
Patrik Dahlen, CEO Immunovia
Email: patrik.dahlen@immunovia.com
Tel: +46 73 376 76 64
This is information that Immunovia AB (publ) is obliged to
make public pursuant to the Securities Market Act. The information
was submitted for publication at 16.00 CET on March 12, 2021.
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently in the final validation phase. The company aims for a
sales start at the end of Q1 2021 with subsequent commercial
testing in Q2.
When validated, IMMray™ PanCan-d will be the first blood-based
test for early diagnosis of pancreatic cancer on the market, with a
potential to significantly improve patient survival and
outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-publishes-the-annual-report-for-the-financial-year-2020,c3305642
The following files are available for download:
https://mb.cision.com/Main/13121/3305642/1386177.pdf
|
Immunovia Annual
Report 2020 (PDF)
|